Expert Consensus on the Lipid Management of Diabetic Patients(2024 Edition)
Diabetes is a significant independent risk factor for atherosclerotic cardiovascular disease(ASCVD),with dyslipidemia playing a critical role in the initiation and progression of ASCVD in diabetic patients.Currently in China,the prevalence of dyslipidemia in diabetes is high,while the control rate remains low.Therefore,to enhance lipid management in patients with diabetes,the Endocrinology and Metabolism Physician Branch of Chinese Medical Doctor Association,in collaboration with the Experts'Committee of National Society of Cardiometabolic Medicine,has convened experts to develop a consensus on the management of dyslipidemia in patients with type 1 or type 2 diabetes.The development of this consensus is informed by the existing practices in lipid management among Chinese diabetic patients,incorporating contemporary evidence-based findings and guidelines from national and international sources.The consensus encompasses the lipid profile characteristics,the current epidemiological status of dyslipidemia,ASCVD risk stratification,and lipid management procedures in diabetic patients.For the first time,both low-density lipoprotein cholesterol(LDL-C)and non-high-density lipoprotein cholesterol(non-HDL-C)have been recommended as primary targets for lipid intervention in diabetic patients.The consensus also includes a summary and recommendations for lipid management strategies in special diabetic populations,including children and adolescents,individuals aged 75 years and older,patients with chronic kidney disease,metabolic-associated fatty liver disease,as well as those who are pregnant.This comprehensive consensus will contribute to the dissemination of key clinical advancements and guide clinical practice,aiming to improve cardiovascular outcomes in diabetic patients.
NETL
NSTL
万方数据
